Includes new, competitive renewal and supplemental awards.
See additional awards here: https://medicine.uiowa.edu/research/scientific-impact/deans-list-new-funding-awards
December 2023
| PI | Sponsor | Title |
| Sanjana Dayal | NIH RO1 4 years |
Preventive mechanisms of Age-associated Thrombosis |
| Nabeel Hamzeh | Bristol-Myers Squibb Company 3 years |
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis |
November 2023
| PI | Sponsor | Title |
| Yi Huang | NIH R01 3 years |
Role of LSD1 in Triple Negative Breast Cancer Development and Therapeutic Response |
| Umar Farooq | Cargo Therapeutics 5 years |
An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CART-cell |
| Umar Farooq | Janssen Research & Development, Inc. 4 years |
A Phase 1b Multicenter, Open-label, Study of JNJ-90009530, an Autologous Anti-CD20 CAR-T Cell Therapy in Adult Participants with Relapsed or Refractory B-cell Non- Hodgkin Lymphoma |
| Dilek Ince | Corixa Corporation 3 years |
A Phase 2b, randomized, controlled, open-label study to evaluate the immune response and safety of the RSVPreF3 OA investigational vaccine in adults (50 years of age) when administered to lung and renal transplant recipients comparing 1 versus 2 doses an |
| Douglas Laux | Replimune, Ltd. 3 years |
A Phase 2, Open-label, Multicenter Study Investigating RP3 in Combination with Other Therapy in Patients with Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck |
| Douglas Laux, Mohammed Milhem | Seagen, Inc. 3 years |
A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors |
| Sneha Phadke | AstraZeneca Pharmaceuticals LP 3 years |
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/ |
| Sabrina Tan | Ansun Biopharma, Inc. 3 years |
A Phase III Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS 181 for the Treatment of Lower Respiratory Tract Parain:fluenza Infection in Immunocompromised Subjects |
| Yousef Zakharia | Worldwide Clinical Trials, Inc. 3 years |
A PHASE 1B/2 BASKET STUDY OF ACR-368 AS MONOTHERAPY AND IN COMBINATION WITH GEMCITABINE IN ADULT SUBJECTS WITH PLATINUM -RESISTANT OVARIAN CARCINOMA, ENDOMETRIAL ADENOCARCINOMA, AND UROTHELIAL CARCINOMA BASED ON ACRIVON ONCOSIGNATURE STATUS |
October 2023
| PI | Sponsor | Title |
| Grace Ciampa | NIH F31 2 years |
Examining the Function of a Novel Protein in the Cardiac Junctional Membrane Complex |
|
Ernesto Ruiz Duque |
Bristol-Myers Squibb Company 3 years |
DISCOVER-HCM |
| Rami El Abiad | Celldex Therapeutics, Inc. 3 years |
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis |
| Alejandro Comellas | IQVIA RDS Inc. 3 years |
A Phase 3, 52-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-Label Extension of BLU-5937 in Adult Participants with Refractory Chronic Cough, Including Unexplained Chronic Cough (CALM-1) |
| Muhammad Furqan | AbbVie, Inc. 3 years |
A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), carboplatin, or cisplatin in adult subjects with advanced solid tumors. |
| Muhammad Furqan | BeiGene USA 3 years |
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors |
| Muhammad Furqan | Poseida Therapeutics, Inc. 3 years |
A PHASE 1 DOSE ESCALATION AND EXPANDED COHORT STUDY OF P-MUC1C-ALLO1 IN ADULT SUBJECTS WITH ADVANCED OR METASTATIC SOLID TUMORS |
| Sneha Phadke | NSABP Foundation, Inc. 5 years |
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or |
| Brian Link | Mayo Clinic 3 years |
Characteristics and outcomes of patients with Diffuse Large B-cell Lymphoma Receiving Frontline Treatment at Cancer Centers within the LEO Cohort, ML43785 |
September 2023
| PI | Sponsor | Title |
| Umar Farooq | Angiocrine Bioscience, Inc. 3 years |
Angiocrine Long Term Follow-Up Umbrella Study |
| Umar Farooq | Nektar Therapeutics 3 years |
A PHASE 2/3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF NKTR-255 VS PLACEBO FOLLOWING CD19-DIRECTED CAR-T CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA |
| Antonio Sanchez | Merck Sharp & Dohme LLC 3 years |
A Phase 2b Randomized, Double-Blind Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Precirrhotic Nonalcoholic Steatohepatitis |
| Antonio Sanchez | PPD Investigator Services, LLC 3 years |
A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease |
| Christopher Strouse | Poseida Therapeutics, Inc. 3 years |
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects with Relapsed / Refractory Multiple Myeloma (MM) |
August 2023
| PI | Sponsor | Title |
| Aleksander Lenert | NIH K23 3 years |
Investigating Disease Activity, Bone Damage and Interleukin-1 Genes in Adult SAPHO Syndrome and Chronic Nonbacterial Osteomyelitis |
| Marcelo Correia | Lilly USA, LLC 3 years |
A Phase 3, Open-Label Study of Once Daily LY3502970 Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4) |
| Umar Farooq | ImmPACT Bio USA Inc. 3 years |
A PHASE 1/2 MULTI-CENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF IMPT-314, A CD19/20 BISPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY IN PARTICIPANTS WITH RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA |
| Muhammad Furqan | AGRESSIVE B-CELL NON HODGKIN LYMPHOMA 3 years |
A Randomized, Open-label, Phase 3 Study of Tarlatamab Compared With Standard of Care in Subjects With Relapsed Small Cell Lung Cancer After Platinum-based First-line Chemotherapy (DeLLphi-304) |
| Muhammad Furqan | Elicio Therapeutics, Inc. 3 years |
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects with Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS viral oncogene homolog (NRAS) Mutated Solid Tumors |
| Asad Javed | Lyell Immunopharma, Inc. 3 years |
A Phase 1 Study to Assess the Safety and Efficacy of LYL845 in Adults with Relapsed and/or Refractory Metastatic or Locally Advanced Melanoma and Selected Solid Tumor Malignancies |
| Mohammed Milhem | Merck Sharp & Dohme LLC 8 years |
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE- 010) |
| Sneha Phadke | Arvinas Estrogen Receptor Inc. 3 years |
An Open-Label, Randomized, Non-Comparative Phase 2 Study of ARV-471 or Anastrozole in Post-Menopausal Women With ER+/HER2- Breast Cancer in the Neoadjuvant Setting |
| Philip Polgreen | Pfizer, Inc 4 months |
Developing approaches to estimate a more accurate measure of the burden of influenza |
| Ernesto Ruiz Duque | Bristol-Myers Squibb Company 3 years |
ODYSSEY-HCM |
July 2023
| PI | Sponsor | Title |
| Sabrina Tan | NIH R01 - 4 years | Molecular Determinants of MG53 in heart structure and function |
| Tomohiro Tanaka | US DoD, CDMRP k08 5 years |
Estimating the Causal Effect of Liver Allocation Policy Reflecting the Heterogeneity from Age and Geography |
| Loreen Herwaldt | University of Wisconsin-Madison 2 years |
Povidone-iodine to Stop Access-Related Infections and Transmission of Staphylococcus Aureus (PAINTS) |
| Sneha Phadke | Olema Pharmaceuticals, Inc. 3 years |
A Phase 1b Open-Label Multicenter Study of OP-1250 in Combination with the CDK4/6 Inhibitor Ribociclib or with the PI3K Inhibitor Alpelisib in Adult Subjects with Advanced and/or Metastatic HR Positive, HER2 Negative Breast Cancer |
| Tomohiro Tanaka | PPD Investigator Services, LLC 3 years |
Phase 3 Multicenter, Randomized, Double-Blind, Study to Assess the Efficacy and Safety of Treatment with Bepirovirsen in HBeAg-negative Nucleos(t)ide Analogue-treated Participants with Chronic Hepatitis B Virus (B-Well 1) |
| George Weiner | V Foundation for Cancer Research 4 years |
T cell help and resistance to anti-cancer monoclonal antibody therapy |
| Yousef Zakharia | Astellas Pharma Global Development, Inc. 3 years |
A Phase 1 Study of ASP1002 in Participants with Metastatic or Locally Advanced Solid Tumors |
| Yousef Zakharia | AstraZeneca LP 3 years |
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients I |
See additional awards here: https://medicine.uiowa.edu/research/scientific-impact/deans-list-new-funding-awards